Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
5.74 AUD
-9.89%
Market Closed
Updated:
May 20, 2024
Mayne Pharma Group Ltd
Accumulated Depreciation
|
Mayne Pharma Group Ltd
Accumulated Depreciation Peer Comparison
Comparables:
RCE
NEU
BOT
PBP
C
CU6
Competitive Accumulated Depreciation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Accumulated Depreciation
-AU$57.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Accumulated Depreciation
-AU$616.1k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Accumulated Depreciation
-AU$229.7k
|
CAGR 3-Years
-49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Accumulated Depreciation?
Accumulated Depreciation
-57.2m
AUD
-57.2m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Accumulated Depreciation amounts to -57.2m AUD.
What is Mayne Pharma Group Ltd's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-7%
-7%
Over the last year, the Accumulated Depreciation growth was 55%. The average annual Accumulated Depreciation growth rates for Mayne Pharma Group Ltd have been 14% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
